Literature DB >> 14871535

Quantification and detection of DcR3, a decoy receptor in TNFR family.

Jinguo Chen1, Lurong Zhang, Sunghee Kim.   

Abstract

A soluble decoy receptor, DcR3, belongs to the tumor necrosis factor receptor (TNFR) family, and this receptor is known to bind to three TNF family ligands, namely Fas ligand (FasL), LIGHT, and TL1A. To aid our understating of the role of DcR3 in the immune system, we have developed quantitative enzyme-linked immunosorbent assay (ELISA) to detect soluble DcR3 in human biological fluids. Two monoclonal antibodies, MD3E2 and MD3B1, that recognized different epitopes on the DcR3 molecule were selected as capture and detection antibodies, respectively, to be paired in ELISA. The assay had a detection limit of 36 pg/ml with a dynamic range of 0.25-16 ng/ml. The recovery range was 91-112% for cell culture supernatant and 90-108% for human sera. Intra- and inter-assay CVs were less than 7.2% and 11.2%, respectively. Among a panel of cell lines tested, colon adenocarcinoma cell line, SW480, secreted the highest levels of DcR3 at 3.2 ng/ml. From the screening of human sera samples, we discovered that 39 healthy individuals, 59 tumor patients, and 46 patients with renal failure expressed an average (mean+/-S.D.) 0.56+/-0.52, 2.3+/-1.6, and 4.6+/-2.8 ng/ml DcR3, respectively. To confirm the specificity of ELISA, we have purified native DcR3 from SW480 cell culture supernatants and identified a native DcR3 in a clinical serum by immunoprecipitation. Taken together, our data demonstrated that the ELISA developed in this study was specific and sensitive to quantify soluble DcR3 in a variety of human biological fluids and that the assay would be useful for studying the regulation of DcR3 in certain pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871535     DOI: 10.1016/j.jim.2003.11.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

Review 1.  Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.

Authors:  Carl F Ware
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

2.  Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.

Authors:  Jing Tong; Ran Ao; Ying Wang; Bing Chang; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients.

Authors:  Szu-Chun Hung; Ta-Wei Hsu; Yao-Ping Lin; Der-Cherng Tarng
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 8.237

4.  Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.

Authors:  Hong-Wei Shen; Shun-Liang Gao; Yu-Lian Wu; Shu-You Peng
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

5.  MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival.

Authors:  Ran Ao; Ya-Qi Du; Ying Wang; Yu-Shuai Chen; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2013-09-01

6.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.

Authors:  Hiroshi Maruyama; Kouichi Hirayama; Miho Nagai; Itaru Ebihara; Homare Shimohata; Masaki Kobayashi
Journal:  Clin Rheumatol       Date:  2016-06-01       Impact factor: 2.980

8.  Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression.

Authors:  Wei Wang; Xinfeng Li; Weimin Sun; Lurong Zhang; Mei Zhang; Benzu Hong; Guorong Lv
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-13       Impact factor: 4.553

9.  Significance of increased expression of decoy receptor 3 in chronic liver disease.

Authors:  S Kim; V Kotoula; P Hytiroglou; D Zardavas; L Zhang
Journal:  Dig Liver Dis       Date:  2009-02-04       Impact factor: 4.088

10.  Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis.

Authors:  Sunghee Kim; Lijun Mi; Lurong Zhang
Journal:  Diagn Microbiol Infect Dis       Date:  2012-05-29       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.